#United States #Atlanta #MetaVia #DA-1726 #ObesityWeek

MetaVia Inc. and DA-1726's Breakthrough Presentation

MetaVia Inc., a biotechnology firm dedicated to addressing cardiometabolic diseases, made significant waves recently by announcing the presentation of new Phase 1 and pre-clinical data on their innovative drug, DA-1726, at the upcoming ObesityWeek® 2025. The event is set to occur both in person and virtually from November 4 to November 7, 2025, in Atlanta, Georgia.

The research highlights DA-1726 as a dual oxyntomodulin (OXM) analog that operates as an agonist for both glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). This dual action positions DA-1726 as a pivotal player in the treatment of obesity, a concern that is increasingly significant in public health discussions.

Phase 1 trials demonstrated that the drug has a favorable safety profile and tolerability. Participants in the trial experienced not only meaningful reductions in body weight but also in waist circumference, showcasing its efficacy without dose titration—a characteristic that adds to the convenience for patients. Additionally, DA-1726 displayed significant lipid-lowering effects, comparable to existing treatments like pemvidutide, making it a promising candidate in obesity management.

As Hyung Heon Kim, CEO of MetaVia, remarked, the results from this trial reinforce DA-1726’s potential to serve as a groundbreaking dual agonist in obesity treatment. The overall safety profile observed, combined with the drug's ability to promote early and significant weight loss, is seen as a substantial advancement in addressing obesity and its related complications. Moreover, the pharmacokinetic (PK) analysis revealed a favorable linear and dose-proportional exposure, allowing for once-weekly dosing to improve patient adherence and experience.

The findings from the Phase 1 study are particularly compelling. At the 32 mg dosage level, participants achieved an average body weight reduction of 4.3% after just 26 days, with some experiencing reductions of up to 6.3%. Waist circumference reductions of up to 3.9 inches were also noted, with effects lasting for two weeks beyond the treatment period. Importantly, the trial found that DA-1726 was well-tolerated, as evidenced by the absence of serious adverse events, a key consideration in any clinical trial.

Comparisons with Other Treatments

When comparing effects on body weight and lipid metabolism, DA-1726 outperformed current therapies such as tirzepatide, also achieving similar appetite suppression and energy expenditure without necessitating higher food intake. The data suggested that weight loss occurred primarily due to enhanced energy expenditure instead of increased physical activity—an important distinction for patient management strategies.

The pre-clinical findings shed light on DA-1726's potential advantages over existing obesity therapies. Notably, DA-1726 achieved comparable weight loss to pemvidutide while delivering superior lipid-lowering outcomes. The evident reductions in total cholesterol and LDL-C levels indicate that DA-1726 could provide additional cardiovascular benefits alongside its primary weight-loss effects.

Following these innovative breakthroughs, MetaVia is also extending the Phase 1 study to evaluate long-term effects and tolerance at the 48 mg dose, aiming for a comprehensive understanding of DA-1726's efficacy and safety. Results from this extended trial are anticipated later this year.

In summary, MetaVia Inc. is charting new territory in the fight against obesity with DA-1726. As the company prepares for the upcoming presentations at ObesityWeek® 2025, the data presented promises to shed further light on how DA-1726 can change the landscape of obesity treatment, potentially offering new hope for patients struggling with weight management and related metabolic diseases.
For further details regarding this clinical trial, please refer to Clinical Trials (NCT06252220).